-
Mashup Score: 22Nitin Jain, MD, on Innovative Therapies in CLL - 8 hour(s) ago
Hagop Kantarjian, MD, professor and chair in the Department of Leukemia at the University of Texas MD Anderson Cancer Center, and Nitin Jain, MD, a professo…
Source: www.youtube.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3
Dr. Coombs discussed time limited therapies and the phase III AMPLIFY trial of acalabrutinib plus venetoclax in CLL.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🎉 @calliecoombsmd, of @UCIrvine, shares what she is most looking forward to in #CLL research and treatment at #SOHO2024! 📺 Watch here: https://t.co/mkff7NEiyO https://t.co/AzrrrlChw0
-
-
Mashup Score: 3
The newer agents have distinguished themselves especially by having safety profiles superior to ibrutinib.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🙌 @calliecoombsmd, of @UCIrvine, gave a history and overview of BTK inhibitors for #CLL management at #SOHO2024! 📺 Watch here: https://t.co/i8gntpcN1s https://t.co/b54sVTcceo
-
-
Mashup Score: 0Study Establishes Median PFS, OS Benefits of Ibrutinib in Older Patients With CLL, SLL | Blood Cancers Today - 1 month(s) ago
When compared to chlorambucil, ibrutinib provides significantly longer PFS and OS benefits and a high response rate with manageable long-term safety in CLL.
Source: bloodcancerstoday.comCategories: General Medicine News, Oncologists1Tweet-
🙌 Ibrutinib provides a high response rate, manageable safety, and longer PFS than chlorambucil in older patients with #CLL. 📝 Read more from the RESONATE-2 study led by Jan Burger MD, PhD, of @MDAndersonNews, and presented at #SOHO2024. ➡️ https://t.co/yutxzQZ6wJ https://t.co/6CKcPWEXFi
-
-
Mashup Score: 2
Fixed-duration ibrutinib plus venetoclax provides durable PFS in patients with CLL, with effective retreatment options after disease progression.
Source: bloodcancerstoday.comCategories: General Medicine News, Hematologists1Tweet-
➕ Ibrutinib plus venetoclax yields durable PFS in #CLL, according to a study led by William G. Wierda, MD, PhD, of @MDAndersonNews, and presented at #SOHO2024. ➡️ https://t.co/XgSsJ8AglV https://t.co/OVpKJckzCg
-
-
Mashup Score: 1Oral Inhibitors Safe for CLL Patients With Severe Renal Dysfunction | Blood Cancers Today - 1 month(s) ago
Oral targeted inhibitors are a viable treatment for patients with CLL with severe renal dysfunction, but potential dose adjustments are necessary to ensure tolerability.
Source: bloodcancerstoday.comCategories: General Medicine News, Hematologists1Tweet-
💊 Oral inhibitors are safe for Patients with #CLL with severe renal dysfunction, according to a study presented at #SOHO2024 by Clare Anderson, MD, of @DukeMedSchool. 📰 https://t.co/1zRjnaxgtX https://t.co/gWxjQyFv0D
-
-
Mashup Score: 6Dr. Rogers Discusses Takeaways From the CLL Debate at SOHO 2024 | Blood Cancers Today - 1 month(s) ago
Dr. Rogers debated against Inhye Ahn, MD, on whether therapy with Bruton tyrosine kinase inhibitors can be discontinued for patients with CLL.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
⭐ @KerryARogersMD, of @OSUCCC_James, discusses the key takeaways from the #CLL debate at #SOHO2024, which examined whether therapy with Bruton tyrosine kinase inhibitors can be discontinued. 📺 Watch here: https://t.co/7EpQ6oemml https://t.co/VMfBmqji5E
-
Watch the full discussion between @DrHKantarjian and @NitinJainMD on #CLL, BTK inhibitors, and more during #SOHO2024 on YouTube at https://t.co/64ekDwarIU https://t.co/py2ekfhaL1